Literature DB >> 21887126

Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease.

Ahmet Emre Eskazan1, Hamida Akmurad, Seniz Ongoren, Ozden Ozer, Burhan Ferhanoglu.   

Abstract

Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia (AIHA) generally caused by IgM autoantibodies which exhibit maximal reactivity at 4°C. CAD can be idiopathic or secondary to some diseases and/or conditions. Only a minority of cases of secondary AIHA in non-Hodgkin's lymphoma (NHL) are associated with cold antibodies. Diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHLs with a proportion of nearly 30% of all adult cases. 40% of patients with DLBCL have an extranodal disease or at least disease initially confined to extranodal sites. The most common extranodal site is the gastrointestinal tract. We present a patient with primary gastrointestinal DLBCL who presented with CAD and was treated with a CHOP-Rituximab regimen.

Entities:  

Keywords:  Cold agglutinin disease; Diffuse large B cell lymphoma; Gastrointestinal involvement

Year:  2011        PMID: 21887126      PMCID: PMC3153337          DOI: 10.1159/000328445

Source DB:  PubMed          Journal:  Case Rep Gastroenterol        ISSN: 1662-0631


Introduction

Autoimmune hemolytic anemia (AIHA) is a term used for anemias caused by destruction of erythrocytes by antibodies that are directed against membrane antigens of the patients' red blood cells (RBCs). Among all kinds of anemias, AIHA is an uncommon form. Even among the groups of hemolytic anemias, AIHA is not the most common variant and no more than 5-10 patients with AIHA per year are diagnosed [1]. The majority of AIHA cases are mediated by warm-reactive autoantibodies, i.e. antibodies displaying optimal reactivity with human RBCs at 37°C and which are usually of the IgG immunoglobulin class. In contrast, cold agglutinin disease (CAD) is generally caused by IgM autoantibodies which exhibit maximal reactivity at 4°C. CAD can be idiopathic or secondary to some diseases and/or conditions (e.g. Mycoplasma pneumoniae infection, infectious mononucleosis, other viral infections or malignant diseases such as lymphoproliferative disorders). Only a minority of cases of secondary AIHA in non-Hodgkin's lymphoma (NHL) are associated with cold antibodies. In a cohort of 370 patients with NHL, 1.1% had cold reacting antibodies [2]. Diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHLs with a proportion of nearly 25-30% of all adult cases [3]. 40% of patients with DLBCL have extranodal disease or at least disease initially confined to extranodal sites [4]. The most common extranodal site is the gastrointestinal tract. We present a patient with primary gastrointestinal DLBCL who presented with CAD.

Case Report

A 46-year-old otherwise healthy female patient was admitted to the outpatient clinic of our hematology department with fatigue and anemia in November 2010. Before that she saw another physician and her hemoglobin (Hb) level was found to be 9.8 g/dl; a diagnosis of iron deficiency anemia was made and she was put on oral iron replacement therapy. Since her complaints did not resolve and her Hb level decreased to 4.8 g/dl, she was admitted to our institution. Physical examination revealed paleness in the mucous membranes and subicterus; no peripheral lymphadenopathy or organomegaly was detected. The interesting thing about her complete blood count was that her hematocrit (Hct) was discordant with her Hb level (Hb: 4.8 g/dl; Hct: 9%) and she had a high mean corpuscular volume of 115.7 fl, mean cell Hb of 64.3 pg and mean cell Hb concentration of 55.6 g/dl with automated counter. White blood cell and platelet counts were normal. Agglutination was seen in anticoagulated blood at room temperature and disappeared upon warming the blood to 37°C; repeating the complete blood count after warming the blood avoided this problem. Peripheral blood smear revealed RBC clumps. Her reticulocyte was as high as 16% and direct antibody (Coombs) test was positive, so AIHA and CAD was thought to be the diagnosis. Cold agglutinin test was found to be positive with a titer of 1/2,560 and cryoglobulinemia was excluded. In her blood chemistry lactate dehydrogenase was 520 U/l (normal 125-243), indirect bilirubin was 2.76 mg/dl and haptoglobin level was low. Serum protein electrophoresis and serum immunoglobulin levels were normal. 80 mg/day methylprednisolone with folic acid replacement therapy was initiated. Epstein-Barr virus, cytomegalovirus, herpes simplex virus, hepatitis B and C viruses as well as human immunodeficiency virus were serologically negative and serology for Mycoplasma pneumoniae was also found to be negative. She had no signs of arthritis, Raynaud phenomenon or any other rheumatological diseases. Thoracic and abdominal computed tomography (CT) was done in order to exclude lymphoproliferative disorders. Thoracic CT was normal whereas abdominal CT revealed increased wall thickness in a segment of the terminal ileum. There were also mesenteric and paraaortic lymphadenopathies 20 mm in diameter. A colonoscopy was performed, a mass in the lumen of terminal ileum was detected and a biopsy was taken ( ). Histopathological evaluation of the biopsy specimen was consistent with DLBCL. Positron emission tomography-computed tomography (PET-CT) showed an increased uptake of F-18 fluorodeoxyglucose (FDG) in the terminal ileum ( ). Bone marrow infiltration was detected and there were no complaints of B symptoms, so the patient was staged as IVAE disease with an international prognostic index score of 2. CHOP (cyclophosphamide 750 mg/m2/day D1, Adriamycin 50 mg/m2/day D1, vincristine 2 mg/day D1 and methylprednisolone 80 mg/day D1-5) chemotherapy with Rituximab 375 mg/m2/day D1 (R-CHOP) was initiated. After administering the chemotherapy, her Hb and Hct levels gradually increased and the hemolysis resolved in the following days; after the second course of R-CHOP she was discharged from the hospital.

Colonoscopy was performed and a mass in the lumen of the terminal ileum was detected.

PET-CT showed an increased FDG uptake in the terminal ileum.

Discussion

AIHA may be associated with either IgG antibodies which react with the RBC surface at warm temperature or with (usually) IgM antibodies which react below body temperature. The latter are therefore named ‘cold agglutinins’. Cold agglutinins are IgM antibodies reacting with untreated adult red cells (anti-I) or reacting with fetal or cord red cells (anti-i). CAD accounts for 13-15% of cases of AIHA [5]. CAD can be primary or cold agglutinins are produced either in response to infection or secondary to neoplastic growth of a single B cell clone. Economopoulos et al. reviewed 370 patients with NHL and found that 23 (6.2%) had AIHA, 4 of whom (1.1%) had cold reacting antibodies [2]. Sallah et al. published characteristics of 16 patients with NHL and AIHA out of a cohort of 501 patients, of whom 3 had CAD and only 1 had a diagnosis of DLBCL [6]. 25 patients with high-grade NHL and AIHA were demonstrated in the literature, 22 of them had DLBCL [7]. Berentsen et al. found 76% of patients with chronic CAD to have underlying lymphoma and most of the cases were lymphoplasmacytic lymphoma, marginal zone lymphoma and small lymphocytic lymphoma/chronic lymphocytic leukemia [8]. About 3.5% of patients with CAD and indolent NHL progressed to DLBCL within a median observation time of 5 years. This was not the scenario in our patient because she did not have a diagnosis of low-grade lymphoma before the diagnosis of DLBCL was made. DLBCL presenting with CAD is a rare entity. The association of CAD with extranodal presentations of NHL has been characterized [8]. Airaghi et al. published a patient with DLBCL with adrenal and renal involvement and CAD [9]. Another DLBCL patient with gastrointestinal involvement and CAD was published in the literature before [10], but he had extensive disease with gastrointestinal involvement and bone marrow infiltration with hemophagocytic syndrome and polyneuropathy, and the diagnosis was made postmortem. Our patient also had gastrointestinal involvement and bone marrow infiltration, but neither hemophagocytosis nor polyneuropathy was detected. Níáinle et al. published a DLBCL patient with nodal disease, bone marrow involvement and CAD [11], and a DLBCL case with isolated bone marrow involvement and cold agglutinins was described before [12]. Our patient had no nodal disease, only a mass in the terminal ileum, and although lymph nodes were detected by abdominal CT, they did not show FDG uptake on PET-CT. Since in secondary CAD the underlying disease should be promptly treated, we started R-CHOP in order to overwhelm the clinical picture. In conclusion, CAD accounts for 15% of cases of AIHA and most of the cases are chronic lymphocytic leukemia and lymphoma (most commonly low-grade NHLs). The association between CAD and DLBCL is rare, extranodal DLBCL with cold agglutinins is even rarer. Here we present a case of DLBCL with gastrointestinal and bone marrow involvement and CAD. To our knowledge, our case is the only reported case of CAD in a patient with primary gastrointestinal involvement of DLBCL.

Disclosure Statement

None of the authors has any conflict of interest to declare.
  11 in total

Review 1.  Unusual presentation of large B cell lymphoma: a case report and review of literature.

Authors:  L Airaghi; I Greco; M Carrabba; M Barcella; I M Baldini; P Bonara; M Goldaniga; L Baldini
Journal:  Clin Lab Haematol       Date:  2006-10

2.  Diffuse large B-cell lymphoma with isolated bone marrow involvement presenting with secondary cold agglutinin disease.

Authors:  F Níáinle; O-P R Hamnvik; C Gulmann; C Bermingham; J Kelly; P Mc Evoy; P Murphy
Journal:  Int J Lab Hematol       Date:  2008-01-18       Impact factor: 2.877

3.  [Which are the true incidence rates of primary hematological disorders acquired in our population?].

Authors:  E Franco-García; P Giraldo; M Bernal; D Rubio-Félix; M Giralt
Journal:  Sangre (Barc)       Date:  1998-10

4.  [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases].

Authors:  I Genty; M Michel; O Hermine; A Schaeffer; B Godeau; H Rochant
Journal:  Rev Med Interne       Date:  2002-11       Impact factor: 0.728

5.  Autoimmune hemolytic anemia in patients with non-Hodgkin's lymphoma: characteristics and significance.

Authors:  S Sallah; G Sigounas; P Vos; J Y Wan; N P Nguyen
Journal:  Ann Oncol       Date:  2000-12       Impact factor: 32.976

6.  Cold agglutinin disease in non-Hodgkin's lymphoma.

Authors:  T Economopoulos; N Stathakis; M Constantinidou; E Papageorgiou; C Anastassiou; S Raptis
Journal:  Eur J Haematol       Date:  1995-07       Impact factor: 2.997

Review 7.  Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas.

Authors:  Alexander W Hauswirth; Cathrin Skrabs; Christian Schützinger; Alexander Gaiger; Klaus Lechner; Ulrich Jäger
Journal:  Leuk Lymphoma       Date:  2007-06

8.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Ruth Langholm; Klaus Beiske; Henrik Hjorth-Hansen; Waleed Ghanima; Jon Hjalmar Sørbø; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

9.  [Anti-Pr2 cold agglutinin disease with polyneuropathy evolving to malignant lymphoma].

Authors:  K Takai; M Sanada; H Shibuya
Journal:  Rinsho Ketsueki       Date:  1992-09

Review 10.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

View more
  5 in total

1.  Cold agglutinin-mediated autoimmune haemolytic anaemia associated with diffuse large B cell lymphoma.

Authors:  Sariya Wongsaengsak; Magdalena Czader; Attaya Suvannasankha
Journal:  BMJ Case Rep       Date:  2018-07-10

Review 2.  Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy.

Authors:  Sigbjørn Berentsen; Tatjana Sundic
Journal:  Biomed Res Int       Date:  2015-01-29       Impact factor: 3.411

Review 3.  Role of Complement in Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Transfus Med Hemother       Date:  2015-09-07       Impact factor: 3.747

4.  Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component.

Authors:  M Christina Cox; Arianna Di Napoli; Stefania Scarpino; Gerardo Salerno; Caterina Tatarelli; Caterina Talerico; Mariangela Lombardi; Bruno Monarca; Sergio Amadori; Luigi Ruco
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

5.  Two cases of primary cold agglutinin disease associated with megaloblastic anemia.

Authors:  Shinsaku Imashuku; Naoko Kudo; Katsushige Takagishi; Katsuyasu Saigo
Journal:  Case Rep Hematol       Date:  2015-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.